Unmasking the Genetic Code Behind Breast Cancer Resistance

Researchers from TMC and NIBMG have uncovered key genomic factors contributing to hormone treatment resistance in breast cancer. The study identifies mutations in three genes, DNA repair deficiencies, and telomere shortening as culprits. These findings promise advancements in personalized treatments for Indian patients, paving the way for future clinical trials.

Researchers at the Tata Memorial Centre in Mumbai and the National Institute of Biomedical Genomics in West Bengal announced a breakthrough in breast cancer research. They have identified genomic factors associated with resistance to hormone treatment. This discovery holds potential to reshape treatment strategies in India.

Breast cancer, making up 28.2% of female cancers in India, affects approximately 200,000 women annually. A significant subtype involves the presence of the estrogen receptor protein in the cells. The study pinpointed three relapse drivers: mutations in three key genes, DNA repair issues, and telomere shortening.

Funded by the Department of Biotechnology's Virtual National Cancer Institute programme, this research emphasizes the importance of understanding genetic diversity for developing precise treatments. Future clinical trials are on the horizon to apply these insights, focusing on patient-specific treatment customization to improve outcomes.